Bacterial infection profiles in lung cancer patients with febrile neutropenia

Jean-Philippe Lanoix, Emilie Pluquet, Francois Xavier Lescure, Houcine Bentayeb, Emmanuelle Lecuyer, Marie Boutemy, Patrick Dumont, Vincent Jounieaux, Jean Luc Schmit, Charles Dayen, Youcef Douadi, Jean-Philippe Lanoix, Emilie Pluquet, Francois Xavier Lescure, Houcine Bentayeb, Emmanuelle Lecuyer, Marie Boutemy, Patrick Dumont, Vincent Jounieaux, Jean Luc Schmit, Charles Dayen, Youcef Douadi

Abstract

Background: The chemotherapy used to treat lung cancer causes febrile neutropenia in 10 to 40% of patients. Although most episodes are of undetermined origin, an infectious etiology can be suspected in 30% of cases. In view of the scarcity of data on lung cancer patients with febrile neutropenia, we performed a retrospective study of the microbiological characteristics of cases recorded in three medical centers in the Picardy region of northern France.

Methods: We analyzed the medical records of lung cancer patients with neutropenia (neutrophil count < 500/mm(3)) and fever (temperature > 38.3°C).

Results: The study included 87 lung cancer patients with febrile neutropenia (mean age: 64.2). Two thirds of the patients had metastases and half had poor performance status. Thirty-three of the 87 cases were microbiologically documented. Gram-negative bacteria (mainly enterobacteriaceae from the urinary and digestive tracts) were identified in 59% of these cases. Staphylococcus species (mainly S. aureus) accounted for a high proportion of the identified Gram-positive bacteria. Bacteremia accounted for 60% of the microbiologically documented cases of fever. 23% of the blood cultures were positive. 14% of the infections were probably hospital-acquired and 14% were caused by multidrug-resistant strains. The overall mortality rate at day 30 was 33% and the infection-related mortality rate was 16.1%. Treatment with antibiotics was successful in 82.8% of cases. In a multivariate analysis, predictive factors for treatment failure were age >60 and thrombocytopenia < 20000/mm(3).

Conclusion: Gram-negative species were the most frequently identified bacteria in lung cancer patients with febrile neutropenia. Despite the success of antibiotic treatment and a low-risk neutropenic patient group, mortality is high in this particular population.

Figures

Figure 1
Figure 1
Flow charts.

References

    1. Remontet L. Estimations nationales: tendances de l'incidence et de la mortalité par cancer en France entre 1978 et 2000. pp. 190–193. BEH 41-42/2003.
    1. Institut national de prévention et éducation pour la santé. Actualités Tabac. N° 2 juin/juillet. 1999.
    1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433–53. doi: 10.1016/j.ejca.2006.05.002.
    1. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold Ch, Burghouts J. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo controlled phase III study. Ann Oncol. 2001;12:1359–1368. doi: 10.1023/A:1012545507920.
    1. Cullen M, Steven MD, Billingham L, Gaunt C, Hastings M. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–998. doi: 10.1056/NEJMoa050078.
    1. Ray-Coquard I. Facteurs pronostics des neutropénies fébriles. Bulletin du Cancer. 2006;93:501–506.
    1. Hughes TW, Armstrong D, Bodey GP. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751. doi: 10.1086/339215.
    1. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother. 1998;41:7–11. doi: 10.1093/jac/41.suppl_4.7.
    1. Poyart C, Morand P, Buzyn A. Étiologie des infections bactériennes chez les patients neutropéniques fébriles: rôle du laboratoire dans le diagnostic. Presse Med. 2004;33:460–466. doi: 10.1016/S0755-4982(04)98633-2.
    1. Cordonnier C, Buzyn A, Leverger G. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis. 2003;36:149–158. doi: 10.1086/345435.
    1. Markman M, Abeloff MD. Management of hematologic and infectious complications of intensive induction therapy for small cell carcinoma of the lung. Am J Med. 1983;74:741–746. doi: 10.1016/0002-9343(83)91061-6.
    1. Matsui K, Masuda N, Takada M, Kusunoki Y, Fukuoka M. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Japan J Clin Oncol. 1991;21:428–434.
    1. Niho S, Ohe Y, Goto K. Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Japan J Clin Oncol. 2004;34:69–73. doi: 10.1093/jjco/hyh019.
    1. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999;341:312–318. doi: 10.1056/NEJM199907293410502.
    1. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.
    1. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30S:S51–9.
    1. Rikimaru T, Ichiki M, Ookubo Y, Matumoto K, Mimori Y. Pronostic significance of febrile episodes in lung cancer patients receiving chemotherapy. Support Care Cancer. 1998;6:396–401. doi: 10.1007/s005200050183.
    1. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1995;39:445–452.
    1. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996;40:1108–1115.
    1. Berghmans T, Sculier JP, Klastersky J. A prospective study of infections in lung cancer patients admitted to the hospital. Chest. 2003;124:114–120. doi: 10.1378/chest.124.1.114.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever